Using a fluorescent dye to guide cancer surgery in children and young people
Tests indocyanine green dye during surgery to remove children's tumours and lymph nodes.
Key facts
- Who runs it
- The University Of Birmingham
- Where
- Utrecht, NetherlandsSee the site
- Trial code
- EU 2024-514089-37-00
- ISRCTN26150156
- Registry title
- Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 16 Jun 2026
- Expected to end
- 1 Sept 2027
- Type of study
- Interventional
- Record updated
- 30 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people having cancer surgery, including surgery for pulmonary metastasis, a renal tumour or para-testicular rhabdomyosarcoma. Surgery uses ICG and near infrared fluorescence.
- Sex
- All sexes can join.
- Disease stage
- Cohort 2: any renal tumour needing surgery and sampling of lymph nodes behind the abdomen (retroperitoneal). Cohort 3: para-testicular rhabdomyosarcoma, confirmed or presumed, with planned sampling of lymph nodes on the same side (RPLND). Surgery is open, or keyhole (thoracoscopic, transperitoneal or retroperitoneoscopic).
- Earlier treatment
- Patients cannot join if they have already been randomised in Cohort 1 or in the same cohort. Patients cannot join if they are due to receive radioactive iodine as part of treatment.
Main reasons for not taking part
- Allergy to ICG, iodine or iodides
- Known hyperthyroidism
- eGFR <15 ml/min/1.73 m2
- Female patients who are breastfeeding
- Neonates needing exchange transfusion
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Undergoing surgery via open laparotomy and/or thoracotomy, minimally invasive thoracoscopic, transperitoneal or retroperitoneoscopic surgery
- Documented negative pregnancy test for female patients of childbearing potential within 7 days of trial entry
- Sexually active male and female patients of childbearing potential must agree to use adequate and highly effective contraception while on study up until discharge
- Written informed consent from the patient, parent or guardian
- Cohort 2: Any renal tumour requiring surgical resection and retroperitoneal lymph node sampling
- Cohort 3: Histologically confirmed or presumed diagnosis of para-testicular RMS (ptRMS) with the intention to sample nodes from the ipsilateral retroperitoneum according to template dissection. Otherwise known as Retroperitoneal Lymph Node Dissection (RPLND)
Who cannot take part
- Cohort 2: Have entered a previous randomisation within Cohort 1
- Cohort 3: Have entered a previous randomisation within Cohort 1
- Have entered a previous randomisation within the same cohort
- Allergic to ICG
- Allergic to iodine or iodides
- eGFR <15 ml/min/1.73 m2
- Cohort 2: Renal tumour requiring extensive retroperitoneal or hilar dissection to access normal renal parenchyma for the ICG injection as this could damage the lymphatic vessels
- Due to receive radioactive iodine as part of treatment
- Known Hyperthyroidism
- Female patients who are breastfeeding
- Neonates requiring exchange transfusion
- Cohort 2: Kidney wholly replaced by tumour on pre-operative imaging
Where in Netherlands
- Prinses Maxima Centrum voor Kinderoncologie B.V.Utrecht, NetherlandsTaking people
About the trial
What the trial wants to find out
• To identify number of lymph nodes removed in patients having a nephroureterectomy for renal cancer where surgery includes the use of ICG/NIRF for lymph node harvest and compare this data to those who have had the same surgery but without the use of ICG/NIRF • To identify number of lymph nodes removed during retroperitoneal lymph node dissection (RPLND) for paratesticular rhabdomyosarcoma in patients having ICG guided nodal harvest
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- GLO-Surgery: Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
- Plain-language title
- Using a fluorescent dye to guide cancer surgery in children and young peopleGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 April 2026